ImmunoMet Therapeutics was founded in 2015 as a spin-off from HanAll Biopharma in Korea, with a focused mandate: develop lixumistat into a clinical cancer drug addressing one of oncology's most stubborn challenges: resistance to existing treatments.
For the latest clinical data, the investor deck, or media enquiries, get in touch.
